CRESCENT BIOPHARMA, INC. (CBIO): Nasdaq/NYSE listing notice — GlycoMimetics gets Nasdaq extension to June 16, 2025; stock transferred to Capital Market

CRESCENT BIOPHARMA, INC.

Received 180-day extension until June 16, 2025 to meet $1.00 minimum bid price for continued listing.
Common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective December 20, 2024.
If bid price closes at $1.00 or more for 10 consecutive business days before deadline, compliance is achieved.
Company may consider a reverse stock split to regain compliance; no assurance of success.
Failure to comply by June 16, 2025 may lead to delisting, subject to appeal.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CRESCENT BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 19, 2024, GlycoMimetics, Inc. (the “ Company ”) received a notice (the “ Extension Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market (“ Nasdaq ”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until June 16, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). In connection with the Extension Notice, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to

View on SEC.gov

18 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-016472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.